Xinghua Han

1.1k total citations
54 papers, 676 citations indexed

About

Xinghua Han is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xinghua Han has authored 54 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 28 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Xinghua Han's work include Ferroptosis and cancer prognosis (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer-related molecular mechanisms research (6 papers). Xinghua Han is often cited by papers focused on Ferroptosis and cancer prognosis (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer-related molecular mechanisms research (6 papers). Xinghua Han collaborates with scholars based in China and Taiwan. Xinghua Han's co-authors include Yueyin Pan, Nannan Lu, Yifu He, Tao Zhu, Mingming Wu, Peter E. Lobie, Xiao Zhang, Qiong Zhou, Qingqing Sun and Xiaojun Qian and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Xinghua Han

53 papers receiving 671 citations

Peers

Xinghua Han
Shogo Okazaki Japan
Margo P. Cain United States
Kuan‐Li Wu Taiwan
EunGi Kim South Korea
Karama Asleh Canada
Guoxian Long China
Man Chu China
Shogo Okazaki Japan
Xinghua Han
Citations per year, relative to Xinghua Han Xinghua Han (= 1×) peers Shogo Okazaki

Countries citing papers authored by Xinghua Han

Since Specialization
Citations

This map shows the geographic impact of Xinghua Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinghua Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinghua Han more than expected).

Fields of papers citing papers by Xinghua Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinghua Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinghua Han. The network helps show where Xinghua Han may publish in the future.

Co-authorship network of co-authors of Xinghua Han

This figure shows the co-authorship network connecting the top 25 collaborators of Xinghua Han. A scholar is included among the top collaborators of Xinghua Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinghua Han. Xinghua Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wan, Mengting, Benjie Shan, Hongwei Jin, et al.. (2025). Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment. Molecular Cancer. 24(1). 61–61. 18 indexed citations
2.
3.
Cao, Ting, Le Huang, Mingming Wu, et al.. (2025). Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4. Frontiers in Cell and Developmental Biology. 13. 1563353–1563353. 2 indexed citations
4.
Chen, Jian, Nannan Lu, Song Wang, et al.. (2025). Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis. Breast Cancer Research. 27(1). 64–64. 1 indexed citations
5.
Wang, Miaomiao, Wang Ya, Yong Zhu, et al.. (2024). LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance. Oncogene. 43(17). 1249–1262. 5 indexed citations
6.
Li, Yan, Haiyang Yu, Xinghua Han, & Yueyin Pan. (2024). Analyses of hypoxia-related risk factors and clinical relevance in breast cancer. Frontiers in Oncology. 14. 1350426–1350426. 3 indexed citations
7.
8.
Lu, Nannan, Lei Zhang, Xiang Li, et al.. (2023). Immune microenvironment and clinical feature analyses based on a prognostic model in lymph node-positive breast cancer. Frontiers in Oncology. 13. 1029070–1029070. 1 indexed citations
9.
Zhang, Jinguo, et al.. (2023). Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment. Frontiers in Immunology. 14. 1073550–1073550. 3 indexed citations
10.
Wu, Mingming, Xiao Zhang, Weijie Zhang, et al.. (2022). Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nature Communications. 13(1). 1371–1371. 107 indexed citations
11.
Shan, Benjie, Xinghua Han, Xiaotian Zhao, et al.. (2022). Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer. Frontiers in Oncology. 11. 784985–784985. 19 indexed citations
12.
13.
14.
Lu, Nannan, Jie Dong, Xin Fang, et al.. (2021). Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI. BMC Medical Imaging. 21(1). 155–155. 3 indexed citations
15.
Liu, Yu, Xinghua Han, Yueyin Pan, et al.. (2021). An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer. Frontiers in Immunology. 12. 704655–704655. 7 indexed citations
16.
Shan, Benjie, Wei Jin, Xinghua Han, et al.. (2020). Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study. Gland Surgery. 9(4). 1026–1035. 3 indexed citations
17.
Zhou, Qiong, Jie Dong, Xiaodong Jiang, Yueyin Pan, & Xinghua Han. (2020). Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment. Open Medicine. 15(1). 659–662. 3 indexed citations
18.
Yan, Li, et al.. (2019). miR-128 Functions as an OncomiR for the Downregulation of HIC1 in Breast Cancer. Frontiers in Pharmacology. 10. 1202–1202. 13 indexed citations
19.
Huang, Dabing, Yong Wang, Yifu He, et al.. (2018). Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancer. Cancer Cell International. 18(1). 168–168. 14 indexed citations
20.
Pan, Feng, Jing Tian, Yifu He, et al.. (2012). Association of TNF-α-308 and -238 Polymorphisms with Risk of Cervical Cancer: A Meta-analysis. Asian Pacific Journal of Cancer Prevention. 13(11). 5777–5783. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shogo Okazaki Breakdown of academic impact, for papers by Margo P. Cain Breakdown of academic impact, for papers by Kuan‐Li Wu Breakdown of academic impact, for papers by EunGi Kim Breakdown of academic impact, for papers by Karama Asleh Breakdown of academic impact, for papers by Guoxian Long Breakdown of academic impact, for papers by Man Chu
Rankless by CCL
2026